Slade Stephen
Alcon Laboratories Inc, USA.
J Refract Surg. 2004 Sep-Oct;20(5):S601-5. doi: 10.3928/1081-597X-20040901-37.
To evaluate the differences in outcomes between CustomCornea and CustomVue LASIK treatments on different eyes of the same patient 1 month after surgery.
Thirty-five patients were enrolled in two phases of a prospective study and treated with Alcon CustomCornea LASIK (Alcon Laboratories Inc, Fort Worth, Tex) on one eye and VISX CustomVue LASIK (VISX, Santa Clara, Calif) on the fellow eye. Twenty-five patients were treated in phase I without nomogram adjustments and ten patients were treated in phase II with nomogram adjustments made to the VISX CustomVue treatments only. Standard clinical outcomes such as visual acuity and manifest refraction were evaluated as well as quality of vision measures such as subjective questionnaires, contrast sensitivity, and higher order optical aberrations.
In the phase I group, 92% of the CustomCornea eyes and 72% of the CustomVue eyes were within 0.50 diopters (D) of their attempted correction. In the phase II group, with a nomogram applied to the CustomVue eyes, 80% of the CustomCornea eyes and 100% of the CustomVue eyes were within 0.50 D of their attempted correction. There was no loss of 22 lines of best spectacle-corrected acuity for the CustomCornea or CustomVue eyes in either phase I or phase II. Wavefront analysis demonstrated that the CustomVue eyes had statistically significantly more spherical aberrations at 1 month compared to the CustomCornea eyes in the phase I and II groups. An average increase in mesopic contrast sensitivity at spatial frequencies was seen for the CustomCornea eyes in phase II and in only one spatial frequency for the CustomVue eyes in phase II.
At 1 month after LASIK, the CustomCornea eyes showed superiority in the number of eyes seeing 20/20 or better uncorrected visual acuity, constrast sensitivity at 3 and 12 cpd, and the amount of postoperative spherical aberration. After nomogram adjustment, CustomVue eyes had a more accurate refractive outcome. Patients were satisfied or extremely satisfied with both systems, 92%-100%.
评估术后1个月时，同一患者不同眼睛接受CustomCornea和CustomVue准分子原位角膜磨镶术（LASIK）治疗后的效果差异。
35例患者参与了一项前瞻性研究的两个阶段，一只眼睛接受爱尔康CustomCornea LASIK（爱尔康实验室公司，沃思堡，德克萨斯州）治疗，另一只眼睛接受威视（VISX）CustomVue LASIK（威视公司，圣克拉拉，加利福尼亚州）治疗。25例患者在第一阶段接受治疗，未进行列线图调整，10例患者在第二阶段接受治疗，仅对VISX CustomVue治疗进行列线图调整。评估标准临床结果，如视力和显验光，以及视觉质量指标，如主观问卷、对比敏感度和高阶光学像差。
在第一阶段组中，92%的CustomCornea眼睛和72%的CustomVue眼睛在预期矫正值的0.50屈光度（D）范围内。在第二阶段组中，对CustomVue眼睛应用列线图后，80%的CustomCornea眼睛和100%的CustomVue眼睛在预期矫正值的0.50 D范围内。在第一阶段或第二阶段，CustomCornea或CustomVue眼睛均未出现最佳矫正视力下降2行及以上的情况。波前分析表明，在第一阶段和第二阶段组中，与CustomCornea眼睛相比，CustomVue眼睛在术后1个月时的球差在统计学上显著更多。第二阶段中，CustomCornea眼睛在空间频率处的中视对比敏感度平均增加，而CustomVue眼睛仅在一个空间频率处增加。
LASIK术后1个月时，CustomCornea眼睛在未矫正视力达到20/20或更好的眼睛数量、3和12周/度的对比敏感度以及术后球差量方面表现更优。经列线图调整后，CustomVue眼睛的屈光结果更准确。患者对两种系统的满意度或极度满意度均为92%-100%。
